Kira Health Invest

Kira Pharmaceuticals is a clinical-stage biotechnology company focused on developing next-generation complement-targeted therapies for patients with immune-mediated diseases. The company's lead candidate, KP104, is a first-in-class bifunctional biologic designed to simultaneously target the C5 and C3 complement pathways, offering potentially superior efficacy over existing single-target inhibitors. Kira utilizes its proprietary LOGIC platform to engineer therapies with improved potency and tissue-targeting capabilities, particularly for liver-mediated complement production. With a presence in both the United States and China, the company is advancing a diverse pipeline across hematology, nephrology, neurology, and ophthalmology.